Aarey Drugs Allots 1.15 Million Shares

1.15 million equity shares have been issued by Aarey Drugs following warrant conversion.
The total capital infusion from this latest allotment amounts to Rs 5.5 crore.

Reader Takeaway: The equity base expands via warrant conversion, providing capital but resulting in shareholder dilution.

What just happened

Aarey Drugs & Pharmaceuticals Ltd. held a board meeting on September 30, 2026, approving the allotment of 1,150,000 fully paid-up equity shares. These shares were issued at a price of Rs 63.80 each, which includes a face value of Rs 10 and a premium of Rs 53.80. This conversion process has successfully brought an infusion of Rs 5,50,27,500 into the company.

Why this matters

For investors, this corporate action directly alters the company's capital structure. The total number of outstanding equity shares has risen to 31,874,303. While the conversion signals capital infusion, it also results in the dilution of existing equity for current shareholders. Monitoring these conversions is essential for evaluating earnings per share metrics.

Warrant Conversion Status

The company originally issued 5,000,000 convertible warrants on May 23, 2025. To date, a total of 3,520,000 warrants have been converted into equity. Following the recent issuance, there are 1,480,000 warrants remaining. These outstanding warrants can still be converted within the 18-month window set from the initial issue date in May 2025.

What to track next

Investors should closely watch for updates regarding the remaining 1,480,000 warrants. Any further conversion will trigger additional equity issuance and further dilution. Keeping an eye on the company's official filings will clarify whether these remaining warrants are exercised before the expiry of the 18-month tenure.